Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09HNV
|
|||
| Former ID |
DNCL002785
|
|||
| Drug Name |
Intedanib
|
|||
| Synonyms |
Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Approved | [1] | |
| Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Approved | [2] | ||
| Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 3 | [3] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [4], [5], [6] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [4], [7] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H33N5O4
|
|||
| Canonical SMILES |
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
|
|||
| InChI |
1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
|
|||
| InChIKey |
CPMDPSXJELVGJG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 656247-17-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14836969, 24116377, 44845702, 56435863, 76307381, 99431587, 99432362, 103654502, 109693020, 124343350, 124756932, 125163739, 126583666, 126724182, 131465103, 134964383, 135264167, 135267499, 136340157, 136920292, 139351111, 143498980, 144115708, 152236441, 152258852, 152344119, 160647702, 162011437, 162037383, 162202550, 162205188, 164041723, 172232574, 174531531, 174561006, 177748905, 178102559, 180386833, 188899496, 198986794, 223388548, 223471427, 223685460, 223704774, 223896861, 226755113, 226755114, 249738349, 249807126, 251963000
|
|||
| ChEBI ID |
CHEBI:85164
|
|||
| ADReCS Drug ID | BADD_D01597 ; BADD_D02470 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936). | |||
| REF 5 | ClinicalTrials.gov (NCT01979952) Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||
| REF 6 | ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research. U.S. National Institutes of Health. | |||
| REF 7 | ClinicalTrials.gov (NCT01610869) Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.